PURPOSE: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features. Such patients might benefit from additional therapy in complete remission (CR). Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR. EXPERIMENTAL DESIGN: Tipifarnib 400 mg twice daily for 14 of 21 days was initiated after recovery from consolidation chemotherapy, for a maximum of 16 cycles (48 weeks). RESULTS: Twenty (42%) patients completed 16 cycles, 24 (50%) were removed from study for relapse, and 4 (8%) discontinued drug prematurely for intolerance. Nonhematologic toxicities were rare, but tipifarnib dose was reduced in 58% for myelosuppression. Median disease-free survival (DFS) was 13.5 months (range, 3.5-59+ months), with 30% having DFS >2 years. Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary AML and adverse cytogenetics. CONCLUSIONS: This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy. Future studies are warranted to examine alternative tipifarnib dosing and continuation beyond 16 cycles.
PURPOSE:Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features. Such patients might benefit from additional therapy in complete remission (CR). Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR. EXPERIMENTAL DESIGN:Tipifarnib 400 mg twice daily for 14 of 21 days was initiated after recovery from consolidation chemotherapy, for a maximum of 16 cycles (48 weeks). RESULTS: Twenty (42%) patients completed 16 cycles, 24 (50%) were removed from study for relapse, and 4 (8%) discontinued drug prematurely for intolerance. Nonhematologic toxicities were rare, but tipifarnib dose was reduced in 58% for myelosuppression. Median disease-free survival (DFS) was 13.5 months (range, 3.5-59+ months), with 30% having DFS >2 years. Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary AML and adverse cytogenetics. CONCLUSIONS: This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy. Future studies are warranted to examine alternative tipifarnib dosing and continuation beyond 16 cycles.
Authors: N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: R M Stone; D T Berg; S L George; R K Dodge; P A Paciucci; P P Schulman; E J Lee; J O Moore; B L Powell; M R Baer; C D Bloomfield; C A Schiffer Journal: Blood Date: 2001-08-01 Impact factor: 22.113
Authors: D Grimwade; H Walker; G Harrison; F Oliver; S Chatters; C J Harrison; K Wheatley; A K Burnett; A H Goldstone Journal: Blood Date: 2001-09-01 Impact factor: 22.113
Authors: J E Karp; J E Lancet; S H Kaufmann; D W End; J J Wright; K Bol; I Horak; M L Tidwell; J Liesveld; T J Kottke; D Ange; L Buddharaju; I Gojo; W E Highsmith; R T Belly; R J Hohl; M E Rybak; A Thibault; J Rosenblatt Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: Javier Bolaños-Meade; Judith E Karp; Chuanfa Guo; Clarence B Sarkodee-Adoo; Aaron P Rapoport; Michael L Tidwell; Laxmi N Buddharaju; T Timothy Chen Journal: Leuk Res Date: 2003-04 Impact factor: 3.156
Authors: Daniel A Arber; Anthony S Stein; Nora H Carter; David Ikle; Stephen J Forman; Marilyn L Slovak Journal: Am J Clin Pathol Date: 2003-05 Impact factor: 2.493
Authors: R A Mesa; J K Camoriano; S M Geyer; W Wu; S H Kaufmann; C E Rivera; C Erlichman; J Wright; A Pardanani; T Lasho; C Finke; C Y Li; A Tefferi Journal: Leukemia Date: 2007-06-21 Impact factor: 11.528
Authors: Nan Soon Wong; Kellen L Meadows; Lee S Rosen; Alex A Adjei; Scott H Kaufmann; Michael A Morse; William P Petros; Yali Zhu; Paul Statkevich; David L Cutler; Michael L Meyers; Herbert I Hurwitz Journal: Cancer Invest Date: 2011-11 Impact factor: 2.176
Authors: Michael A Morgan; Fredrick O Onono; H Peter Spielmann; Thangaiah Subramanian; Michaela Scherr; Letizia Venturini; Iris Dallmann; Arnold Ganser; Christoph W M Reuter Journal: J Mol Med (Berl) Date: 2011-09-14 Impact factor: 4.599